Syros Pharmaceuticals (SYRS) Doses First Patient in SY-1425 Phase 2 in AML, MDS
Tweet Send to a Friend
Syros Pharmaceuticals (Nasdaq: SYRS) announced that the first patient has been dosed in the Phase 2 clinical trial of its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
